바이오사이토젠의 고도화 면역 결핍 마우스인 B-NDG 마우스는 인간 PBMC와 hHSC (CD34+ hematopoietic stem cells)를 이식하기에 좋은 도구입니다. 이 인간화 면역 세포가 이식된 모델들은 인간 면역 세포에서 면역항암제의 효과를 검증하기 위한 강력한 도구이며, CDX 와 PDX 모델에서의 효능 평가를 위해서도 유용합니다. 아울러 이 모든 CDX 모델에 대하여 PD(pharmacodynamic 서비스 또한 제공하고 있습니다.

보유중인CDX 모델



Cell linesTumor typeCell linesTumor type
Human solid tumor cell linesNCI-H1975Lung carcinoma, non-small cellZR-75-1Breast ductal carcinoma
HCC827Lung adenocarcinomaMDA-MB-231Breast adenocarcinoma
NCI-H520Lung carcinomaDU4475Breast carcinoma, triple negative
A549Lung carcinomaMCF7Mammary gland, breast adenocarcinoma
NCI-H1781Lung carcinoma bronchoalveolar5637Bladder grade II carcinoma
HCT-8Colorectal Ileocecal adenocarcinomaA431Epidermoid carcinoma
HCT-116Colon carcinomaLN229Glioblastoma
Colo205Colorectal adenocarcinomaMiapaca-2Pancreatic carcinoma
Human blood tumor cell linesDaudiLymphoma,NAMALWABurkitt’s lymphoma
KG-1Leukemia, acute myelogenous (AML)Kasumi-1Leukemia, acute myeloblastic (AML)
RajiLymphoma, Burkitt’sSU-DHL-1Large cell lymphoma, Diffuse histiocytic lymphoma
K562Leukemia (CML)MV4-11Peripheral blood biphenotypic B myelomonocytic leukemia

루시퍼라아제가 추가된 세포주로 만들어진 CDX 모델

No.Cell nameCancer type
B-HCL-013B-luciferase-GFP Raji Cell LineLymphoma, Burkitt’s
B-MCL-001B-luciferase-GFP HT-29 Cell LineColorectal adenocarcinoma
B-MCL-002B-luciferase-GFP H-1975 Cell LineLung carcinoma, non-small cell
B-HCL-014B-luciferase K562 Cell LineLeukemia (CML)
B-HCL-015B-luciferase MIA PaCa-2 Cell LinePancreatic carcinoma
B-HCL-010B-luciferase U-87MG cell lineGlioblastoma

CDX 마우스 모델에서의 TGK (Tumor Growth Kinetics)

Case 1: HT-29-GFP Luciferase 암세포를 주사한 후 6, 16 , 28일 후의 NOD-scid 마우스의 In vivo 이미지.

A) The mouse on the left was injected with 5 x 106 cells. The mouse on the right was injected with 5 x 105 (B) Signal intensity and tumor size graph.

Case 2: 4T1-Luciferase 암세포를 주사한 후 7, 14 , 21일 후의 NOD-scid 마우스의 In vivo 이미지.

(A) The mouse on the left was injected with 5 x 106 cells; the mice on right was injected with 5 x 105 cells. (B) Signal intensity and tumor size graph.

Case 3: 인간 B 세포 림프종 CDX 모델

Raji cells (5×10⁶) were injected into B-NDG, NOD-scid and BALB/C nude mice. (A) Kaplan-Merier survival curves. (B) Relative body weight change. (C) Percentage of human cells in mouse peripheral blood quantified by q-PCR. (D) Liver tumor nodules. (E) Immunohistochemical staining of livers and spleens.

CDX 약효 평가 결과 예시

Case 1 

Raji-Fluc cells (5 x 10⁵) were injected into B-NDG mice. Antibody X was administered on specified days. (A) Representative in vivo imaging recorded at different time points to monitor tumor progression. (B) Tumor load (as indicated by luciferase activity) kinetic curves post antibody treatment. Early dosing on day 3 in addition to day 10 resulted in robust tumor growth inhibition. In contrast, a single dose at day 10 had little effect.

Case 2 

Humanized B-NDG mice engrafted with human CD34+ HSC were intravenously injected with 5 x 10⁵ Raji-Fluc cells. Five days after Raji-Fluc cells implantation, mice were treated with anti-human PD-1 antibody. (A) Images of tumor load as indicated by luciferase activity. Tumor growth was dramatically inhibited by the human PD-1 antibody at day 7. RC=Raji-Fluc + Control. PDH=Antibody X + Humanized Mice. Naive B-NDG=Untreated Group.

Back to top
카카오톡 상담하기